Randomized Trial Of Platelet Transfusion Policies After Blood Stem Cells Transplantation In Young Children: Reduction Of Number Of Single Platelet Concentrate Donors Per Child

This study is ongoing, but not recruiting participants.

Sponsored by:	Institut Gustave Roussy
Information provided by:	Institut Gustave Roussy
ClinicalTrials.gov Identifier:	NCT00180986

Purpose

Randomized Trial Of Platelet Transfusion Policies After Blood Stem Cells Transplantation In Young Children: Reduction Of Number Of Single Platelet Concentrate Donors Per Child

Condition	Intervention	Phase
Children Treated With High-Dose Chemotherapy (HDC) Followed by Haematopoietic Stem Cell Transplantation (HSCT)	Procedure: Platelet concentrates	Phase III

MedlinePlus related topics: Blood Transfusion and Donation

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title:	Randomized Trial Of Platelet Transfusion Policies After Blood Stem Cells Transplantation In Young Children: Reduction Of Number Of Single Platelet Concentrate Donors Per Child

Further study details as provided by Institut Gustave Roussy:

Primary Outcome Measures:

The primary end point of the study was tocompare the number of platelet concentrates donors who were implicated in platelet transfusion supportive after HSCT.

Estimated Enrollment:	120
Study Start Date:	October 1995

Eligibility

Ages Eligible for Study:	up to 15 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Children weighing 30 kg or less with a diagnosis of haematological malignancy or solid tumour, who were candidates for HSCT were eligible for inclusion in the study.
Written informed consent was required from parents of eligible children.

Exclusion Criteria:

Children were excluded if they had a anti-HLA and/or anti-HPA antibody, if they were prior included in this study or if the parents declined to participate.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00180986

Locations

France
Institut Gustave-Roussy
Villejuif, France, 94800

Sponsors and Collaborators

Institut Gustave Roussy

Investigators

Principal Investigator:

Valérie LAPIERRE, MD

Institut Gustave Roussy

More Information

Study ID Numbers:	Minnie, CSET 94/357
Study First Received:	September 13, 2005
Last Updated:	December 13, 2005
ClinicalTrials.gov Identifier:	NCT00180986
Health Authority:	France: Afssaps - French Health Products Safety Agency

ClinicalTrials.gov processed this record on January 16, 2009